Worth Watching Stocks on the Move: Williams Companies Inc (NYSE:WMB), Valeant Pharmaceuticals Intl Inc (NYSE:VRX)

On Monday, Shares of Williams Companies Inc (NYSE:WMB), included 1.23% and shut at $30.52 inside the end purchasing and offering session. The last exchanging scope of the stock ranges amongst $29.91 and $30.90. The business’ commercial center capitalization is $22.89 Billion with the aggregate fabulous loads of 750.84 million. The Williams Companies, Inc. operates as an energy infrastructure company mainly in the United States. The company operates through Williams Partners, Williams NGL (natural gas liquids) & Petchem Services, and Other segments. It owns and operates natural gas pipeline system extending from Texas, Louisiana, Mississippi, and the offshore Gulf of Mexico through Alabama, Georgia, South Carolina, North Carolina, Virginia, Maryland, Delaware, Pennsylvania, and New Jersey to the New York City metropolitan area. The company also owns and operates a natural gas pipeline system extending from the San Juan basin in northwestern New Mexico and southwestern Colorado through Colorado, Utah, Wyoming, Idaho, Oregon, and Washington to a point on the Canadian border near Sumas, Washington; gulfstream natural gas pipeline system extending from the Mobile Bay area in Alabama to markets in Florida; and constitution pipeline that would connect its gathering system in Susquehanna County, Pennsylvania to the Iroquois Gas Transmission and Tennessee Gas Pipeline systems in New York. In addition, it provides natural gas gathering, treating, processing, and compression; NGL production, fractionation, storage, marketing, and transportation; deepwater production handling and crude oil transportation; and olefin production services, in addition to transports and stores natural gas to local natural gas distribution companies, municipal utilities, direct industrial users, electric power generators, and natural gas marketers and producers. Further, the company extracts, fractionates, treats, stores, and sells ethane/ethylene, propane, propylene, normal butane, isobutene, alky feedstock, and condensate.

Shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), added 2.23% and shut at $18.35 inside the last exchanging session. The rest of the purchasing and offering scope of the stock levels among $17.96 and $18.44. The association’s commercial center capitalization is $6.32 Billion with the general uncommon loads of 341.19 million. Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM) declares its financing plans to facilitate the completion of the acquisition of the North American commercialization rights to RUCONEST® from Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) (“Valeant”), as declared on 9 August 2016.

Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM) declares its financing plans to facilitate the completion of the acquisition of the North American commercialization rights to RUCONEST® from Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) (“Valeant”), as declared on 9 August 2016.

Highlights

1 for 7 Rights Issue of 58,943,624 shares to raise about €12.1 million to existing shareholders

Board of Administration to take up their full allotments under the Rights Issue

New $40 million (€37.7 million) straight debt facility from existing lender Silicon Valley Bank and from Kreos Capital V (UK) Ltd Fund

All remaining funding (€62.0 million) from two new convertible bonds with conversion at premiums of between 25% and 35% to the 20 Day Volume Weighted Average Price

Total Funds to be raised in the funding arrangements amount to €111.8 million, resulting in €85 million after transaction costs, fees and repayment of the US$17 million existing debt (€16.2 million)

Net Funds raised (€85 Million) are for payment of the acquisition of the North American commercialisation rights for RUCONEST of US$60 million (€56.7 million) and a total of €28.3 million for additional marketing and sales investments for  RUCONEST both in the USA and in the EU.

Total shares issued now will be limited to 58,943,750

1 for 7 Rights Issue of 58,943,624 shares to raise about €12.1 million to existing shareholders

Board of Administration to take up their full allotments under the Rights Issue

New $40 million (€37.7 million) straight debt facility from existing lender Silicon Valley Bank and from Kreos Capital V (UK) Ltd Fund

All remaining funding (€62.0 million) from two new convertible bonds with conversion at premiums of between 25% and 35% to the 20 Day Volume Weighted Average Price

Total Funds to be raised in the funding arrangements amount to €111.8 million, resulting in €85 million after transaction costs, fees and repayment of the US$17 million existing debt (€16.2 million)

Net Funds raised (€85 Million) are for payment of the acquisition of the North American commercialisation rights for RUCONEST of US$60 million (€56.7 million) and a total of €28.3 million for additional marketing and sales investments for  RUCONEST both in the USA and in the EU.

Total shares issued now will be limited to 58,943,750

Leave a Reply

Your email address will not be published. Required fields are marked *